Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 7, 2025; 31(41): 110367
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.110367
Published online Nov 7, 2025. doi: 10.3748/wjg.v31.i41.110367
Pescadillo ribosomal biogenesis factor 1 as a therapeutic target in tumor immunotherapy
Jia Yu, Zhi-Gang Ren, Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Bo Yu, Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Fei-Lin Ge, Department of Chinese Medicine, State Key Laboratory of Antiviral Drugs, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Co-first authors: Jia Yu and Bo Yu.
Author contributions: Yu J contributed to the project administration, formal analysis, data visualization and manuscript writing; Yu J and Ren ZG contributed to the study conceptualization; Yu B and Ge FL contributed to the data curation and formal analysis; Ren ZG contributed to the methodology design, project supervision, and data validation. All authors have reviewed, edited, read and agreed to the published version of the manuscript. The efforts put forth by Yu J and Yu B were equal in weight and critical nature for the completion of this investigation and letter, meriting co-first authorship.
Supported by the National Natural Science Foundation of China, No. 82470654; and the Natural Science Foundation Key Project of Henan Province, No. 232300421124.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Gang Ren, Department of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou Uni
Received: June 10, 2025
Revised: September 2, 2025
Accepted: September 28, 2025
Published online: November 7, 2025
Processing time: 151 Days and 18.6 Hours
Revised: September 2, 2025
Accepted: September 28, 2025
Published online: November 7, 2025
Processing time: 151 Days and 18.6 Hours
Core Tip
Core Tip: In gastric cancer and head and neck squamous cell carcinoma, pescadillo ribosomal biogenesis factor 1 (PES1) and programmed death-ligand 1 (PD-L1) show significant co-expression. Across multiple tumor types, elevated PES1 is linked to poor prognosis and aggressive tumor behavior. Our analysis further reveals that PES1 expression negatively correlates with CD8+ T cell infiltration and positively correlates with PD-L1 expression. These findings suggest opportunities for combination cancer immunotherapy, although the molecular basis of PES1-PD-L1 interactions and the therapeutic benefit of dual targeting require further experimental validation.